Rep. Wesley Hunt Critiques CMS Decision on Diabetic Treatment
Rep. Wesley Hunt (R-Texas) expressed concerns over what he called a betrayal of diabetics by “unelected bureaucrats” at the Centers for Medicare and Medicaid Services (CMS), who allegedly reinstated regulations from the Biden administration during the Halloween night government shutdown. This move, he argues, goes against former President Donald Trump’s efforts to limit coverage for skin substitutes crucial for those suffering from diabetes.
In a recent interview, Hunt, an Iraq war veteran and candidate for the Texas Senate, accused the previous administration of trying to impose restrictive rules on skin allografts used by diabetic Medicare patients. He claimed that Trump had effectively halted the policy, only for bureaucrats to quietly reinstate it during the shutdown.
In Hunt’s view, CMS has prioritized special interests over patient welfare. He described the timing of the reinstatement, occurring late on a Friday just before Halloween, as deceptive rather than transparent. “Once again, the Washington bureaucrats at CMS have proven that they serve special interests, not the American people,” he stated, lamenting reduced coverage for vital skin-substitute treatments that help prevent amputations and infections.
Texas Republicans have criticized the CMS decision, deeming it an example of prioritizing industry over individuals. Hunt added, “This rule is a betrayal of patients, doctors and common sense. It exemplifies a bureaucratic system overwhelmed by influential industry players.”
He urged CMS to retract the regulations and pay attention to the needs of citizens rather than lobbyists. Hunt also cautioned that these new rules pose a significant threat not only to patients but to jobs as well, suggesting that reduced financial support for transplants could lead to mass layoffs, especially in Texas.
Hunt detailed his perspective on the timeline, asserting that the controversial policy stems from Biden’s administration. He critiqued the bureaucrats who reinstated the regulations, noting their prior association with an anti-Trump think tank, despite the fact that Trump had suspended the rule.
“Skin replacements are crucial for this group of individuals,” he noted, sharing that he has gained insights into the complexities surrounding these treatments. Despite the high costs for production, Hunt emphasized the necessity of ethical companies in this space to ensure patient access and to ease the burden on the health care system.
Further, he stated, “At the end of the day, the patient loses out,” highlighting the risk that 90% of skin substitute providers may cease operations due to these new rules. According to him, this is a counterproductive legacy of the Biden administration, which may inadvertently harm patients who should be receiving care.
Hunt remarked that Congress was sidelined when these decisions were made, emphasizing the lack of legislative oversight during the Halloween night rule change. His office is reportedly taking steps with colleagues to amend the situation while calling on the White House to act swiftly.
Regarding the technical aspects of the CMS rules, Hunt clarified that they would substantially diminish compensation for skin substitutes, potentially jeopardizing the survival of many affected companies, particularly in Texas, where many of his constituents are employed.
Commentators like Steve Gruber have drawn attention to the timing of the rule changes, suggesting that CMS took advantage of public distractions to reinstate regulations that may heavily impact health care access. Issues related to placenta-based skin allografts, essential for treating chronic wounds, particularly in diabetic patients, have come under scrutiny as more funding was funneled towards these treatments during the pandemic.
Under the new guidelines, reimbursement rates will be based on minimal graft sizes, with many companies potentially facing extinction. Gruber argued that the changes serve to favor a select few providers at the expense of broader access.
In light of these developments, Hunt continues to advocate for accountability within the government, asserting that changes are necessary to support vulnerable patients. His campaign for the U.S. Senate hinges on the premise of preserving the health of citizens while confronting the bureaucratic processes that threaten their well-being.
